Prof Lawrence Steinman, MD. received his BA (physics) from Dartmouth in 1968 and his MD from Harvard (1973). He had a fellowship in chemical immunology at the Weizmann Institute (1974-1977) and was an intern and resident at Stanford University Medical School. Steinman served as the Chair of the Interdepartmental Program in Immunology at Stanford University from 2003-2011. He completed his Honorary PhD at the Hasselt University in 2008. Prof Lawrence Steinman currently is the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford University. He is a member of the National Academy of Medicine, and the National Academy of Sciences, USA. Prof Lawrence Steinman also founded the Steinman Laboratory in Stanford University, which is dedicated to understanding the pathogenesis of autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica. In this laboratory he has developed several new therapies for autoimmunity, including some in Phase 2 clinical trials in multiple sclerosis and type 1 diabetes mellitus, as well as one approved drug, natalizumab. He has also developed microarray technology for detecting autoantibodies to myelin proteins and lipids. His laboratory team employs a diverse range of molecular and cellular approaches to devise new medications for demyelinating diseases, and to help predict which current medications will work at various stages of these diseases.
Prof Lawrence Steinman received the Frederic Sasse Award from the Free University of Berlin in 1994, the John Dystel Prize in 2004 from the National MS Society in the US, the Charcot Prize for Lifetime Achievement in Multiple Sclerosis Research in 2011 from the International Federation of MS Societies, and the Cerami Prize for Translational Research in 2015.
Further achievements Prof Lawrence Steinman has been given include the Anthony Cerami Award in Translational Medicine by the Feinstein Institute of Molecular Medicine in 2015. The US congress awarded Prof Lawrence Steinman the Sen. Jacob Javits Award across 1988 and 2002. Steinman has been involved in two prominent exits: Steinman served on the Board of Directors of Centocor which was sold to Johnson and Johnson for $4.9B USD in 1998. He founded Neurocrine Biosciences (NASDAQ:NBIX Market Cap $6.21B USD) in 1992 and served on their Board of Directors. Neurocrine Biosciences (NASDAQ: NBIX) had an IPO in 1997. Neurocrine Biosciences (NASDAQ:NBIX) is a San Diego, CA based biotechnology company that focuses on neurologic, psychiatric and endocrine related disorders, currently it has three late-stage clinical programs, which is a novel achievement based on Prof Steinman’s initial guidance. It currently has a market cap on the NASDAQ of $9.72B USD.
He has founded three other companies, Tolerion, Transparency Life Sciences and Atreca. Steinman heads the Scientific Advisory Board at Transparency Life Sciences. Prof Lawrence Steinman also serves on the Board of Directors at Atreca and Tolerion.
DR. JONATHAN B ROTHBARD
Chief Executive Officer, Chief Scientific Officer and Co-Founder
Dr Jonathan Rothbard, PhD received his BA from Hamilton College (1973) and his PhD from Columbia with Ronald Breslow (1977). His post-doctoral fellowship was with Gerald Edelman at The Rockefeller University after which he was with Gary Schoolnik at Stanford University Medical School where he published the first of 26 manuscripts with Lawrence Steinman in 1986. Subsequently, he was head of the Molecular Immunology Laboratory at the Imperial Cancer Research Fund in London, where he first collaborated with Prof Sir Marc Feldman (1990).
He left academia to help establish ImmuLogic in Palo Alto, and founding Amylin in San Diego. Amylin, which he founded in 1987, was a pharmaceuticals company engaged in the discovery, development and commercialization of drugs relating to diseases including obesity and diabetes. The success of Amylin led to another appointment at Stanford for Dr Rothbard, followed by the founding of CellGate. Leaving CellGate, he returned to an appointment at Stanford, first in the department of chemistry, then rheumatology, and currently in neurology. Amylin was sold to Bristol-Myers Squibb (NYSE:BMY Market Cap $82.49B USD) in 2012 for $5.4 Billion USD.
Chief Operating Officer and Director
Lawrence Pemble has comprehensive experience in successfully creating, financing and developing biotechnology businesses. He has led companies and individual projects from the development and discovery phases through to financing and further clinical development.
A strong technical, entrepreneurial and corporate finance background, formatively developed within the Private Equity space where Lawrence was a Principal of a Life Science Private Equity Firm and latterly as COO of Publicly Traded and Private Biotechnology and Medical Technology companies. Lawrence currently serves as COO of Hemogenyx Pharmaceuticals PLC, an oncology biotech company listed on the London Stock Exchange.
Lawrence has lead numerous financing rounds, M&A activities, IPOs and has held executive roles, up to and including CEO, for start-up and private equity backed ventures, both in private and public capacities.
Lawrence has a sharp understanding and interest in the regulatory and scientific processes and procedures involved in effectively and efficiently moving young biotechnology companies from their roots to the clinical phases.
Chief Financial Officer
Ozan brings a wealth of knowledge and experience to the Katexco team as an investment banker with in-depth capital markets knowledge. He specializes in helping companies define their corporate strategy, then develop and execute corporate transactions to achieve their goals.
His diverse set of expertise in the life sciences and technology industries with a focus on finance, allows Ozan to build compelling financial strategies for corporations. Throughout his career, Ozan has advised numerous private and public companies on M&A initiatives and was the lead banker on more than 40 financings, where he became an expert at working with complex structures, financial analysis, and deal documentation.
He was most recently Vice President, Investment Banking, at Echelon Partners, and was in charge of Origination mandates, focusing on small and mid-cap issuers. Ozan has an Economics and Finance degree from McGill University and is a CFA Charterholder.